| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702271 | Practical Radiation Oncology | 2017 | 6 Pages |
Abstract
FDG-PET increases the chance of detecting LP of unresectable PDAC after SBRT and can have an important impact on reported outcomes. We recommend obtaining FDG-PET to assess treatment response when evaluating efficacy of SBRT and taking its use into account when comparing clinical data.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Diego A.S. MD, Erqi L. MD, Peter D. MD, Lesley MD, Yi PhD, Andrew MD, Rie MS, Albert C. MD, PhD, Daniel T. MD,